• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A polymorphism in the gene encoding the Fcgamma IIIA receptor is a possible genetic marker to predict the primary response to infliximab in Japanese patients with rheumatoid arthritis.

作者信息

Tsukahara S, Ikari K, Sato E, Yamanaka H, Hara M, Tomatsu T, Momohara S, Kamatani N

出版信息

Ann Rheum Dis. 2008 Dec;67(12):1791-2. doi: 10.1136/ard.2007.086892.

DOI:10.1136/ard.2007.086892
PMID:19005160
Abstract
摘要

相似文献

1
A polymorphism in the gene encoding the Fcgamma IIIA receptor is a possible genetic marker to predict the primary response to infliximab in Japanese patients with rheumatoid arthritis.编码FcγIIIA受体的基因中的一种多态性可能是预测日本类风湿性关节炎患者对英夫利昔单抗初始反应的一种遗传标记。
Ann Rheum Dis. 2008 Dec;67(12):1791-2. doi: 10.1136/ard.2007.086892.
2
Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis.类风湿关节炎患者中Fcγ受体IIIA基因型与对肿瘤坏死因子α阻断剂的反应
Arthritis Rheum. 2007 Feb;56(2):448-52. doi: 10.1002/art.22390.
3
Association between the FCGR3A V158F polymorphism and the clinical response to infliximab in rheumatoid arthritis and spondyloarthritis patients.类风湿关节炎和脊柱关节炎患者中FCGR3A基因V158F多态性与英夫利昔单抗临床反应的关联
Scand J Rheumatol. 2010 Nov;39(6):518-20. doi: 10.3109/03009741003781969. Epub 2010 Jun 21.
4
Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.Fcγ受体IIA和IIIA变体对美国风湿病学会和欧洲抗风湿病联盟制定的类风湿关节炎抗肿瘤坏死因子α治疗反应的影响
Ann Rheum Dis. 2009 Oct;68(10):1547-52. doi: 10.1136/ard.2008.096982. Epub 2008 Oct 17.
5
Fcγ receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis.Fcγ 受体 IIIb 多态性和基线时使用糖皮质激素与类风湿关节炎患者接受英夫利昔单抗输注反应相关。
Ann Rheum Dis. 2011 Feb;70(2):299-304. doi: 10.1136/ard.2010.136283. Epub 2010 Oct 27.
6
The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population.在一大群类风湿性关节炎患者中，共享表位是与英夫利昔单抗选择相关而非与对其反应相关的严重程度标志物。
Ann Rheum Dis. 2006 Mar;65(3):342-7. doi: 10.1136/ard.2005.037150. Epub 2005 Aug 11.
7
Influence of FCGR3A-V212F and TNFRSF1B-M196R genotypes in patients with rheumatoid arthritis treated with infliximab therapy.FCGR3A-V212F和TNFRSF1B-M196R基因对接受英夫利昔单抗治疗的类风湿关节炎患者的影响。
Clin Exp Rheumatol. 2008 Mar-Apr;26(2):340-2.
8
Pharmacokinetic study and Fcgamma receptor gene analysis in two patients with rheumatoid arthritis controlled by low-dose infliximab.两名接受低剂量英夫利昔单抗治疗的类风湿关节炎患者的药代动力学研究及Fcγ受体基因分析
Mod Rheumatol. 2009;19(3):329-33. doi: 10.1007/s10165-009-0158-0. Epub 2009 Mar 3.
9
Comments about the editorial by Bénédicte Mugnier and Jean Roudier entitled "Factors predicting responsiveness to anti-TNFalpha therapy in patients with rheumatoid arthritis: using biotherapies rationally".关于贝内迪克特·穆尼耶（Bénédicte Mugnier）和让·鲁迪耶（Jean Roudier）题为《类风湿关节炎患者抗TNFα治疗反应的预测因素：合理使用生物疗法》的社论的评论
Joint Bone Spine. 2005 Jul;72(4):346-7; author reply 347-8. doi: 10.1016/j.jbspin.2005.01.004. Epub 2005 Mar 24.
10
Polymorphism at position -308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics.肿瘤坏死因子α基因-308位的多态性与类风湿关节炎药物遗传学
Ann Rheum Dis. 2005 May;64(5):793-4. doi: 10.1136/ard.2004.028167.

引用本文的文献

1
The Association between Genetics and Response to Treatment with Biologics in Patients with Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, and Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.遗传因素与生物制剂治疗银屑病、银屑病关节炎、类风湿关节炎和炎症性肠病患者反应的相关性：系统评价和荟萃分析。
Int J Mol Sci. 2024 May 26;25(11):5793. doi: 10.3390/ijms25115793.
2
Pharmacogenetics of Drug Therapies in Rheumatoid Arthritis.类风湿关节炎药物治疗的药物遗传学。
Methods Mol Biol. 2022;2547:527-567. doi: 10.1007/978-1-0716-2573-6_19.
3
Gene Ontology Analysis Highlights Biological Processes Influencing Non-Response to Anti-TNF Therapy in Rheumatoid Arthritis.
基因本体分析突显影响类风湿关节炎抗TNF治疗无反应的生物学过程。
Biomedicines. 2022 Jul 27;10(8):1808. doi: 10.3390/biomedicines10081808.
4
Functional FCGR3A 158 V/F and IL-6 -174 C/G polymorphisms predict response to biologic therapy in patients with rheumatoid arthritis: a meta-analysis.功能性FCGR3A 158 V/F和IL-6 -174 C/G基因多态性预测类风湿关节炎患者对生物治疗的反应：一项荟萃分析。
Rheumatol Int. 2014 Oct;34(10):1409-15. doi: 10.1007/s00296-014-3015-1. Epub 2014 Apr 12.
5
FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn's disease through affecting the ADCC activity.FCGR3A-158 多态性通过影响 ADCC 活性影响英夫利昔单抗在克罗恩病中的生物学反应。
Immunogenetics. 2013 Apr;65(4):265-71. doi: 10.1007/s00251-013-0679-8. Epub 2013 Jan 29.
6
Fcγ receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis.Fcγ 受体 IIIb 多态性和基线时使用糖皮质激素与类风湿关节炎患者接受英夫利昔单抗输注反应相关。
Ann Rheum Dis. 2011 Feb;70(2):299-304. doi: 10.1136/ard.2010.136283. Epub 2010 Oct 27.